| scholarly article | Q13442814 |
| P2093 | author name string | Edgar B | |
| Regårdh CG | |||
| Johansson L | |||
| Lundborg P | |||
| Johnsson G | |||
| Rönn O | |||
| Löfberg I | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 205-211 | |
| P577 | publication date | 1985-08-01 | |
| P1433 | published in | Clinical Pharmacology & Therapeutics | Q1101529 |
| P1476 | title | Felodipine kinetics in healthy men. | |
| P478 | volume | 38 |
| Q34358245 | A population study of the pharmacokinetics of felodipine |
| Q69928690 | Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group |
| Q45358365 | Biliary secretion of felodipine metabolites in man after intravenous [14C]felodipine |
| Q36115910 | Clinical pharmacokinetics of calcium antagonists. An update |
| Q38253565 | Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally). |
| Q39697154 | Clinical pharmacokinetics of felodipine. A summary |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q42285697 | Coffee inhibition of CYP3A4 in vitro was not translated to a grapefruit-like pharmacokinetic interaction clinically. |
| Q38677027 | Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation |
| Q34532617 | Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells |
| Q36235775 | Drug interactions: part II. |
| Q93529960 | Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and after exercise |
| Q42251374 | Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine |
| Q45183952 | Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects |
| Q44074760 | Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. |
| Q39927404 | Effects of ingestion of grapefruit juice or grapefruit on the hypotensive effect and plasma concentrations of dihydropyridine calcium antagonists (amlodipine and nifedipine): a case study |
| Q35479377 | Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients |
| Q61440402 | Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice* |
| Q35196196 | Factors affecting the clinical development of cytochrome p450 3A substrates |
| Q28325479 | Felodipine Clinical Pharmacokinetics |
| Q54099334 | Felodipine in the treatment of patients with severe hypertension and impaired renal function. |
| Q69665183 | Felodipine reduces the absorption of theophylline in man |
| Q69915058 | Felodipine versus prazosin as an addition to a beta-blocker in the treatment of essential hypertension. The Australian Multicentre Study |
| Q39567108 | Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension |
| Q28325222 | Felodipine: A New Dihydropyridine Calcium-Channel Antagonist |
| Q24630998 | Fruit juice inhibition of uptake transport: a new type of food-drug interaction |
| Q37367800 | Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression |
| Q24683430 | Grapefruit juice-drug interactions |
| Q77360264 | Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans |
| Q37818135 | Grapefruit-drug interactions. |
| Q24611177 | Grapefruit-medication interactions: forbidden fruit or avoidable consequences? |
| Q44247783 | Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment |
| Q43726337 | Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. |
| Q34048484 | Metabolism and kinetics of amlodipine in man. |
| Q52614145 | Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers. |
| Q42870433 | Oral availability of fluticasone propionate |
| Q31122462 | Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data |
| Q68448575 | Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects |
| Q34732737 | Pharmacokinetics of barnidipine hydrochloride, a new dihydropyridine calcium channel blocker, in the rat, dog and human |
| Q39513598 | Pharmacokinetics of calcium antagonists under development |
| Q34397822 | Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure |
| Q42277034 | Pharmacokinetics of felodipine in patients with impaired renal function |
| Q42646696 | Pharmacokinetics of felodipine in patients with liver disease |
| Q37268536 | Pharmacokinetics of newer drugs in patients with renal impairment (Part II). |
| Q43222722 | Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets |
| Q31012256 | Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant |
| Q39180627 | Prediction of the extent and variation of grapefruit juice-drug interactions from the pharmacokinetic profile in the absence of grapefruit juice. |
| Q69587984 | Quantitative relationships between structure and microsomal oxidation rate of 1,4-dihydropyridines |
| Q28286591 | Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects |
| Q71149787 | Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients |
| Q90089600 | Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study |
| Q39476375 | The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model |
| Q45948033 | The effect of felodipine on bile flow in pentobarbital anaesthetized rats and conscious rats receiving bile salt supplementation |
| Q50868889 | The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. |
| Q37265500 | Towards quantitative prediction of oral drug absorption |
Search more.